Brief: Organogenesis Announces Successful FDA Meeting And Plan To File BLA For Renu® For Knee Osteoarthritis Pain
06/04/2026 22:37
April 6 (Reuters) - Organogenesis Holdings Inc ORGO.O: ORGANOGENESIS ANNOUNCES SUCCESSFUL FDA MEETING AND PLAN TO FILE BLA FOR RENU® FOR KNEE OSTEOARTHRITIS PAIN ORGANOGENESIS HOLDINGS INC - TO INITIATE ROLLING BLA FOR RENU FOLLOWING SUCCESSFUL FDA MEETING ORGANOGENESIS HOLDINGS INC - BLA SUBMISSION FOR RENU EXPECTED BY END OF 2025 ORGANOGENESIS HOLDINGS INC: TO INITIATE A ROLLING BIOLOGICS LICENSES APPLICATION (BLA) FOR RENU PLANNED BEFORE END OF DECEMBER Source text: ID:nGNXsScbz Further company coverage: ORGO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Organogenesis Holdings
See all newsBrief: Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Organogenesis Q2 Net Product Revenue USD 42.8 Million
Organogenesis Holdings Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers